New Anti-Inflammatory
Ingredient is Available for
Qualified Brands

Rhema is the exclusive manufacturer
licensed to deliver Curcumin BDM30™
to qualified brands.

Patent technology (US ,9782,364 B1) owned by Biologic Publishing Inc dba Biologic Pharmamedical Research. Health Canada (NHPD) approved. NPN 80076140  


This patented product is based on the research done by Franco Cavaleri BSc PhD candidate.

The research proves that elevated levels of bisdemethoxycurcumin, or BDMC, targets inflammation in a way that is different than standard curcumin.

Instead of the trace levels of BDMC, usually between 0.5% to 1.5%, in standard curcumin, we can now provide 30% BDMC and dramatically enhance anti-inflammatory relief.

For more information please read this publication:


Read the Technical Abstract and the science behind the discovery

Mitogen- and stress-activated protein kinase 1 (MSK1) is a nuclear kinase that plays a significant role in transcription regulation. One of the curcuminoids, Curcumin III, from the curcumin extract is shown for the first time here to counteract the recruitment of MSK1 at inflammatory gene promotors Read more...

Read the latest BDM30™ Curcumin Press Release

Vancouver, CANADA, April 19, 2017 – Rhema Health Products Ltd. announced today that it has received approval by Health Canada and a Natural Product Number (NPN) for its much-anticipated Curcumin BDM30™. The product has been selling in the USA, but can now be sold in Canada to Read more...

Frequently Asked Questions

Talk with us to see if BDM30™
would benefit your product line:

Contact Us Today!

Rhema Health Products Limited | Pitt Meadows, British Columbia